Compare Ishares Msci Spain ETF (EWP) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs Medpace Holdings Inc — how do they compare? Ishares Msci Spain ETF trades at $57.77 (market cap $2.30B), while Medpace Holdings Inc trades at $608.65 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 7.3× Ishares Msci Spain ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Ishares Msci Spain ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 40 Days and Medpace Holdings Inc for 14 Days on average.
| EWP | MEDP | |
|---|---|---|
Market Cap | $2.30B | $16.82B |
Volume | 845,747 | 223,093 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $630.19 |
52-Week Low | $48.33 | $393.42 |
Typical Hold Time | 40 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWP, the iShares MSCI Spain ETF, trades at $57.82, down 1.73% on the day amid a bearish technical signal. The ETF offers concentrated exposure to Spanish equities with a discounted 16x P/E and 2.7% yield, heavily weighted in financials and utilities. Recent ECB rate hikes to 2.5% and energy-driven inflation pressures create macroeconomic headwinds for European markets.
While EWP provides attractive valuation and yield, the bearish technical outlook and ECB tightening cycle present near-term challenges. The concentrated portfolio in Spanish banks and utilities offers stability but limits diversification. Upside potential depends on Spain's economic resilience amid broader eurozone pressures.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
